{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:14:59Z","timestamp":1788387299437,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2014.00054","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T15:32:01Z","timestamp":1418743921000},"source":"Crossref","is-referenced-by-count":18,"title":["Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy"],"prefix":"10.3389","volume":"1","author":[{"given":"Cl\u00c3\u00a9ment","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eug\u00c3\u00a8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Couec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Strullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Frampas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00c3\u00afc","family":"Campion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00c3\u00a7oise","family":"Kraeber-Bod\u00c3\u00a9r\u00c3\u00a9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/asheducation-2009.1.523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u00e2\u20ac\u2122s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/pbc.22047","article-title":"Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005","volume":"53","author":"Mbulaiteye","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u00e2\u2030\u00a5 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u00e2\u20ac\u2122s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1054\/bjoc.1999.1083","article-title":"Improved outcome in children with advanced stage B-cell non-Hodgkin\u00e2\u20ac\u2122s lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol","volume":"82","author":"Atra","year":"2000","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/01.mph.0000139772.98685.d2","article-title":"Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the Nordic society of pediatric hematology and oncology","volume":"26","author":"M\u00c3\u00a1rky","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cncr.20382","article-title":"Long-term results of the first Italian association of pediatric hematology and oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92)","volume":"101","author":"Pillon","year":"2004","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00c3\u00a9t\u00c3\u00a9 Fran\u00c3\u00a7aise d\u00e2\u20ac\u2122Oncologie P\u00c3\u00a9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy","volume":"50","author":"Itti","year":"2009","journal-title":"J Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"issue":"11","key":"B15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3109\/10428190903308072","article-title":"Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation","volume":"50","author":"Gallamini","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00431-013-1993-8","article-title":"The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood","volume":"172","author":"Sioka","year":"2013","journal-title":"Eur J Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/2191-219X-3-71","article-title":"Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients","volume":"3","author":"Furth","year":"2013","journal-title":"EJNMMI Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00259-010-1619-6","article-title":"18F-FDG PET\/CT in paediatric lymphoma: comparison with conventional imaging","volume":"38","author":"London","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/cbr.2007.0519","article-title":"(18)F-FDG PET in pediatric lymphomas: a comparison with conventional imaging","volume":"23","author":"Lopci","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1055\/s-2005-872517","article-title":"FDG-PET in 10 children with non-Hodgkin\u00e2\u20ac\u2122s lymphoma: initial experience in staging and follow-up","volume":"217","author":"Amthauer","year":"2005","journal-title":"Klin Padiatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00259-009-1276-9","article-title":"Role of PET\/CT in malignant pediatric lymphoma","volume":"37","author":"Riad","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1148\/radiol.11110936","article-title":"Pediatric non lymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET\/CT versus contrast- enhanced CT for evaluation\u00e2\u20ac\u201ca prospective study","volume":"262","author":"Bakhshi","year":"2012","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/j.ejrad.2009.07.035","article-title":"18F-FDG PET and PET\/CT in Burkitt\u00e2\u20ac\u2122s lymphoma","volume":"75","author":"Karantanis","year":"2010","journal-title":"Eur J Radiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/RLU.0b013e3181a34552","article-title":"Spectrum of FDG PET\/CT findings in Burkitt lymphoma","volume":"34","author":"Zeng","year":"2009","journal-title":"Clin Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MNM.0b013e328334fc14","article-title":"False-positive F-18 FDG uptake in PET\/CT studies in pediatric patients with abdominal Burkitt\u00e2\u20ac\u2122s lymphoma","volume":"31","author":"Riad","year":"2010","journal-title":"Nucl Med Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1365-2141.2012.09026.x","article-title":"Burkitt lymphoma: staging and response evaluation","volume":"156","author":"Sandlund","year":"2012","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12284","article-title":"Role of 18f-Fdg-Pet\/Ct in the management of Burkitt lymphoma","author":"Carrillo-Cruz","year":"2014","journal-title":"Eur J Haematol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u00ce\u201dSUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1007\/s00259-011-1741-0","article-title":"Prognostic value of interim FDG PET\/CT in Hodgkin\u00e2\u20ac\u2122s lymphoma patients treated with interim response-adapted strategy: comparison of international harmonization project (IHP), Gallamini and London criteria","volume":"38","author":"Le Roux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Medicine"],"original-title":[],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T13:55:02Z","timestamp":1566136502000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2014.00054\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":30,"URL":"https:\/\/doi.org\/10.3389\/fmed.2014.00054","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,16]]}}}